Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.

Related Articles Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019 May 23;: Authors: Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V Abstract BACKGROUND: Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment of inflammatory bowel disease. AIMS: To determine the efficacy and safety of JAK inhibitors compared to placebo for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). METHODS:…

Read More

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life.

The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life. Aliment Pharmacol Ther. 2019 May 22;: Authors: Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A Abstract BACKGROUND: CT-P13, a biosimilar of the reference product infliximab, has been approved for the treatment of ulcerative colitis on the basis of the results of trials conducted in patients with spondyloarthritis and rheumatoid arthritis. AIM: To compare the effectiveness and safety of CT-P13 and the reference product in infliximab-naive patients with ulcerative…

Read More

Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.

Related Articles Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther. 2019 May 16;: Authors: Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA Abstract BACKGROUND: Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior conventional immunomodulating therapy. AIM: To report effectiveness, safety and therapeutic drug monitoring in a cohort of patients with prolonged…

Read More

The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study.

Related Articles The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study. Aliment Pharmacol Ther. 2019 May 08;: Authors: Malham M, Jakobsen C, Paerregaard A, Virta LJ, Kolho KL, Wewer V Abstract BACKGROUND: Recent studies report increased risks of both cancer and mortality in paediatric onset inflammatory bowel disease (pIBD) but the reproducibility of this is unknown. AIM: In this population-based study we aim to estimate the risk of cancer and mortality in the Danish and Finnish…

Read More

A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease.

A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 May 08;: Authors: McCurdy JD, Israel A, Hasan M, Weng R, Mallick R, Ramsay T, Carrier M Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk of venous thromboembolism (VTE) during hospitalisation and potentially post-discharge. AIMS: To determine the incidence and risk factors for post-discharge VTE in IBD patients and create a point of care predictive model to assess VTE risk. METHODS: Hospitalised IBD patients were identified from our…

Read More

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease.

Related Articles Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease. Aliment Pharmacol Ther. 2019 Apr 15;: Authors: Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D’Haens G Abstract BACKGROUND: The appropriate location for biopsy procurement relative to an ulcer in active Crohn’s disease is unknown. AIM:…

Read More

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? Aliment Pharmacol Ther. 2019 Apr;49(8):1086-1087 Authors: Leong RWL, Kaakoush NO, Yau YY, Wasinger VC PMID: 30920041 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920041?dopt=Abstract

Read More

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply. Aliment Pharmacol Ther. 2019 Apr;49(8):1088-1089 Authors: Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA PMID: 30920043 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920043?dopt=Abstract

Read More

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply.

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply. Aliment Pharmacol Ther. 2019 Apr;49(8):1087-1088 Authors: Bond A, Probert C PMID: 30920048 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30920048?dopt=Abstract

Read More
<< Go Back